BioVector? TALL-104 人急性T淋巴細胞白血病細胞株

BioVector? TALL-104 Human Acute T Lymphoblastic Leukemia Cell Line

第一部分 中文說明

一 產(chǎn)品基本信息與遺傳學背景

• 細胞名稱 BioVector? TALL-104 人急性T淋巴細胞白血病細胞

• 系統(tǒng)學 Accession Cellosaurus CVCL 1729

• 保藏機構(gòu)貨號 ATCC CRL 11386

• 物種來源 人類 Homo sapiens

• 組織與疾病背景 該細胞株建立于一名患有急性T淋巴細胞白血病的兒童患者的外周血。盡管起源于惡性T細胞白血病，但在體外經(jīng)特定細胞因子誘導(dǎo)長期維持培養(yǎng)后，該細胞展現(xiàn)出極其獨特且高效的非特異性細胞毒性殺傷表型。

• 主要表面標志物與表型

  • 表現(xiàn)為 CD3陽性、CD8陽性、CD56陽性、CD2陽性 和 TCR Alpha/Beta陽性。

  • 核心生物學特征 缺乏 CD4、細胞毒性T細胞抗原-4 以及傳統(tǒng)的 CD16 表達。它兼具細胞毒性T淋巴細胞與自然殺傷細胞的殺傷特性，被稱為具有廣譜抗腫瘤活性的MHC非限制性殺傷細胞。

• 生物安全級別 1級。

二 細胞形態(tài)學與特殊培養(yǎng)環(huán)境

• 形態(tài)學特征 展現(xiàn)典型的淋巴母細胞樣特征，細胞呈圓形，在懸浮狀態(tài)下生長，通常會聚集形成大小不一的細胞簇。

• 生長模式 懸浮生長。

• 倍增時間 在添加足量重組人白介素-2的完全培養(yǎng)基中，細胞增殖活躍。

• 標準完全培養(yǎng)基配方

  • 基礎(chǔ)培養(yǎng)基 BioVector? Iscove's Modified Dulbecco's Medium，即IMDM培養(yǎng)基。

  • 維持添加

    • 20% BioVector? 優(yōu)質(zhì)胎牛血清。

    • 必需生長因子 重組人白介素-2，最終濃度為 100 U/mL。注意：缺乏白介素-2將導(dǎo)致該細胞迅速停止增殖并發(fā)生凋亡。

• 物理培養(yǎng)參數(shù) 37攝氏度恒溫、5% 二氧化碳、空氣飽和濕度。

三 細胞傳代與復(fù)蘇標準操作步驟

1. 常規(guī)傳代操作

   • 當細胞密度達到每毫升 8.0乘以10的5次方 至 1.5乘以10的6次方 個細胞，且細胞簇顯著增大時需要進行傳代。

   • 將細胞懸液轉(zhuǎn)移至離心管中，以 150 g離心 5到8分鐘，棄去舊培養(yǎng)基。

   • 用新鮮配制、預(yù)熱并含有 100 U/mL 重組人白介素-2 的 BioVector? 完全培養(yǎng)基重懸細胞。

   • 推薦接種密度 維持在每毫升 2.0乘以10的5次方 至 3.0乘以10的6次方 個細胞。不建議過度稀釋細胞，否則會延長其適應(yīng)期。傳代比例通常為 1比2 至 1比3，每周需要補充或更換培養(yǎng)基 2到3次。

2. 凍存細胞復(fù)蘇

   • 從液氮中取出冷凍管，立即投入 37攝氏度 BioVector? 水浴鍋中快速搖動使其融化，控制在 2分鐘內(nèi)。

   • 將解凍的細胞懸液移至含 9.0 mL 預(yù)熱基礎(chǔ)培養(yǎng)基的離心管中，以 150 g離心 5分鐘以去除殘留的二甲基亞砜。

   • 棄去上清，加入配制好的 BioVector? 完全培養(yǎng)基重懸接種。

四 核心科研應(yīng)用方向

1. 腫瘤免疫治療與效靶殺傷實驗 BioVector? TALL-104 廣泛用作研究抗腫瘤細胞毒性機制的標準效應(yīng)細胞。它能高效殺傷多種同種異體及異種的腫瘤靶細胞，且由于其殺傷活性不受 MHC 限制，常被用于過繼免疫治療的臨床前安全性與有效性評估。

2. NK/T 細胞活化與細胞因子釋放網(wǎng)絡(luò)研究 用于探索在不同共刺激信號或新型小分子藥物干預(yù)下，高效殺傷性 T 細胞分泌干擾素、腫瘤壞死因子及顆粒酶和穿孔素的轉(zhuǎn)錄調(diào)控機制。

3. 新型雙特異性抗體藥效學評價 在開發(fā)靶向 T 細胞表面 CD3 或 CD8 的雙特異性或多特異性抗體時，該細胞株是理想的體外靶向橋接殺傷驗證模型。

PART 2 ENGLISH SECTION

I General Information and Genetic Background

• Cell Line Name BioVector? TALL-104

• Cellosaurus Accession CVCL 1729

• Repository Catalog Number ATCC CRL 11386

• Species Origin Human Homo sapiens

• Tissue and Disease Background Established from the peripheral blood of a pediatric patient diagnosed with Acute T Lymphoblastic Leukemia. Following long term in vitro conditioning with specific cytokines, this line stabilized into a highly unique MHC nonrestricted cytotoxic killer phenotype despite its leukemic lineage.

• Surface Marker Profile

  • Authenticated as CD3 positive, CD8 positive, CD56 positive, CD2 positive, and TCR Alpha/Beta positive.

  • Key Immunological Features Lacks expression of CD4, CTLA-4, and traditional CD16. It bridges the functional attributes of both Cytotoxic T Lymphocytes and Natural Killer cells, acting as a broad spectrum anti tumor effector model.

• Biosafety Level BSL-1.

II Morphological Attributes and Cultivation Media

• Morphology Displays characteristic lymphoblast like round features. Cells expand in suspension and regularly pack into multi cellular clusters of varying sizes.

• Growth Mode Suspension Growth.

• Standard Complete Growth Medium Formulation

  • Basal Medium BioVector? Iscove's Modified Dulbecco's Medium, which is IMDM.

  • Routine Maintenance Supplements

    • 20% premium BioVector? Fetal Bovine Serum.

    • Essential Cytokine Supplement Recombinant Human Interleukin-2 at a final concentration of 100 U/mL. Note The absence of rhIL-2 results in rapid growth arrest and autologous apoptosis.

• Physical Incubation Thresholds Regulated strictly at 37 degrees Celsius under an atmospheric layer of 5% Carbon Dioxide and saturated air humidity.

III Subculturing and Thawing Protocols

1. Routine Passaging Schedule

   • Initiate subculturing when the viable cell concentration reaches 8.0乘以10的5次方 to 1.5乘以10的6次方 cells per mL and clusters become large and dense.

   • Transfer the suspension into a sterile centrifuge tube, pellet at 150 g for 5 to 8 minutes, and aspirate the exhausted medium.

   • Resuspend the cell pellet in freshly prepared, pre warmed BioVector? complete growth medium enriched with 100 U/mL rhIL-2.

   • Recommended Seeding Density Seed fresh cultures at 2.0乘以10的5次方 to 3.0乘以10的5次方 cells per mL. Avoid over diluting the biomass to circumvent prolonged lag phases. The standard split ratio ranges from 1比2 to 1比3, with medium replenishment required 2 to 3 times per week.

2. Cryovial Thawing and Recovery

   • Retrieve the cryovial from liquid nitrogen storage and submerge it immediately into a 37 degrees Celsius BioVector? water bath with continuous agitation until liquefied within 2 minutes.

   • Transfer the mixture into a centrifuge tube containing 9.0 mL of pre warmed basal medium and spin at 150 g for 5 minutes to eliminate DMSO residues.

   • Decant the supernatant, gently loosen the pellet, and re establish the culture in complete BioVector? medium containing 20% FBS and 100 U/mL rhIL-2.

IV Strategic Research Applications

1. Tumor Immunotherapy and Effector to Target Cytotoxicity Assays BioVector? TALL-104 is widely deployed as a premier reference effector cell line to evaluate non MHC restricted anti tumor actions. It effectively lyses a broad array of allogeneic and xenogeneic malignant targets and serves as an in vitro pilot benchmark for adoptive immunotherapy modeling.

2. NK/T Cell Activation Kinetics and Degranulation Networks Utilized to investigate transcriptional and secretory mechanisms behind Interferon Gamma, Tumor Necrosis Factor Alpha, Granzymes, and Perforin release under stimulation by novel small molecule agonists or checkpoint blockers.

3. Evaluation of Bispecific Antibodies Acts as an excellent stable effector model for validating the structural bridge and targeted lysis potential of new bispecific or multi specific antibody formats engineered to engage CD3 or CD8 molecules.

BioVector NTCC質(zhì)粒載體菌株細胞蛋白抗體基因保藏中心

電話:400-800-2947

工作QQ/微信同號:1843439339

網(wǎng)址

http://www.nedfriskphoto.com